



Fax: 866-336-9530  
Toll Free: 1-866-DEO-9530  
E-mail: [investorinfo@deobiosciences.com](mailto:investorinfo@deobiosciences.com)  
[www.deobiosciences.com](http://www.deobiosciences.com)

*John F. Adamson, Jr.  
President & CEO*

January 14, 2022

Dear Investors and Followers:

## Happy 2022!

We can't believe how quickly these months have gone since we first launched our Netcapital offering in 2021. We started at zero and thanks to all of you, we're knocking at the door of six figures in investment raise. Plainly and simply... **THANK YOU** for your investment in DeoBioSciences, Inc. and making this dream come true.

Given that it's the beginning of the year, it's very appropriate to share our upcoming plans for the remainder of the Netcapital campaign and thereafter. First, we're happy with the amount raised so far (although never completely satisfied) and are confident that we can launch our next planned stage strictly with what we've raised so far. Therefore, right now, we don't plan to extend the campaign again. However, if that changes due to the possibility of more last minute investors, etc., we do not foresee the extension being very long. Regardless, this campaign will be closing in the first quarter of 2022.

Second, we are sharing our plans to modify our research strategy to accommodate two changing and important factors: (1) the COVID-19 situation in Ithaca, New York and (2) raised investment below \$140,000. Regarding COVID-19, perhaps many of you have heard in the major news sources that the Cornell University campus was hit with a surge of cases in December. This has resulted in restricted access to some facilities and some personnel availability issues over the last month. While these conditions often "come and go" as part of our new pandemic reality, we suspect that the Cornell campus (and colleges, in general) may be uniquely susceptible to these "spikes" and "outbreaks" given its demographic population of students and faculty who constantly travel from all over the world.

We want to minimize the potential for these conditions to interrupt our research plans in the future, especially once we have resumed our lab activities. So we're planning to conduct the initial R&D outside the Ithaca, New York campus: most likely in a leased wet lab facility in the Atlanta, Georgia metro area. We're currently investigating leasing and logistics options with a couple of local facilities that have great reputations. As a privately leased facility, we could control access to our lab and its availability much more so than if we used an institutional lab space. Also, this move would allow DeoBioSciences decision makers to have immediate and convenient access to and oversight of the work on a daily basis. We may also see some cost savings, as well. We think this is potentially a great "silver-lining" to what initially seemed to be disappointing COVID news. So overall, we're very happy and excited about this "pivot".

Next, regarding how to maximize our research dollars on a reduced investment raise, we're also exploring some exciting adjustments to our plans that we believe will still get the greatest "bang for the buck". We previously stated our intentions to use the investment financing for patient-derived xenografts (PDX) in mice models. However, that was based on meeting a minimum raise goal of

around \$120-140,000. We have searched and identified other PDX models that are also highly predictive but much less expensive and provide faster turnaround times. For example, one new model has been recently introduced by Charles River Labs, called the zebrafish PDX tumor xenograft (ZTX). A fully scalable humanized in vivo system with a 3-day turnaround, the ZTX™ model system complements mouse PDX approaches, allowing us to cost-effectively screen combination treatments and PDX models. This model is not quite the gold standard that the mouse orthotopic PDX model is but it is still very valuable and provides a less expensive route to obtaining strong in vivo data that, if positive, would further validate and de-risk our research. The decision to go this with this attractive PDX model has not yet been finalized but we are strongly considering it based on how much investment we raise in this campaign.

Finally, we do not plan to stop raising investment after Netcapital. We've been approached by multiple parties about raising more capital via differing approaches ranging from Regulation A+ to Regulation D (also known as private placement). It would be inappropriate to name the interested parties now but these accredited investors are potential co-investors in a fundraising round in the future. So, we are keeping our options open for financing to follow this Netcapital offering.

We're all facing a challenging world in 2022 but I just wanted to briefly share our plans for maneuvering and navigating any challenges that we face and our commitment to try our best to determine if our discoveries and technologies can be valuable tools in the world's anticancer toolkit.

Thank you again for being a visionary and fearless ground-floor partner in our journey! More updates to come. Until next time, be well.



John A. & Team DeoBioSciences